Log in automatically

Log in | New user?

SkyePharma

                   

2nd UPDATE: Skyepharma Up On Third Positive Flut

By Jason Douglas OF DOW JONES NEWSWIRES LONDON -(Dow Jones)- Shares in U.K. pharmaceuticals company Skyepharma PLC (SKP.LN) rose more than 10% Thursday after it successfully completed its third phase III study of asthma drug,...

analysis/comments

Skyepharma PLC Announces Research Update

More News related to Press Releases SkyePharma Announces Third FlutiformTM Phase III Efficacy Study Meets Primary Endpoints and Completes Original Core Clinical Trial Programme LONDON, UK, 3 July, 2008 - In a top line analysis...

analysis/comments

                   

UK small cap close down; Armour shares dented on FY profits warning

LONDON (Thomson Financial) - UK small caps suffered substantial losses in Thursday trade, closing down, as the wider markets endured a mixed session, with Armour Group retreating on issuing a full-year profits warning. Armour...

analysis/comments

Comprehensive Evaluation of the UK Pharmaceutical Manufacturers Market

More News related to Press Releases ) has announced the addition of the "Pharmaceutical Manufacturers (UK) - Pharmaceutical Manufacturers is a comprehensive evaluation of the UK market. Using the most up to date information...

analysis/comments

Genaera Corporation Elects Paul K. Wotton to Board of Directors

PLYMOUTH MEETING, Pa., June 30 /PRNewswire-FirstCall/ -- Genaera Corporation today announced the election of Paul K. Wotton, Ph.D., to Genaera's Board of Directors, bringing the membership total to seven. Dr. Wotton is expected...

analysis/comments

                   

Prepared Study Demonstrates Requip-Modutab Is A Highly Effective Treatment In The Management Of...

Main Category: Parkinson's Disease New data presented at the 12th International Congress of Parkinson's Disease and Movement Disorders prove that ropinirole is a highly effective molecule in managing Parkinson's disease (PD)....

analysis/comments

                   

Learn About the Leading Drug Delivery Companies and Technologies: Competitive Landscape, Company...

redorbit.com     24-Jun-2008   1 related          

Posted on: Tuesday, 24 June 2008, 02:30 CDT Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Some key findings from this report... The...

analysis/comments

                   

U.S. FDA Approves Requip®XL?, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For...

studentbmj.com     21-Jun-2008          

GlaxoSmithKline announced the approval of Requip®XL?(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Itis the first and only oral once-daily...

analysis/comments

SKYEPHARMA PLC Consensus Recommendation: HOLD

Released : Thursday, June 19, 2008 3:14 PM Company: SKYEPHARMA PLC Consensus Recommendation: HOLD (Strong Buy: 0, Buy: 2, Hold: 2, Underperform: 0, Sell: 0) Quarter Consensus Estimate [Q2]: N/A FY Consensus Estimate [FY2008]:...

analysis/comments

pharmiweb.co.uk: London City news: SkyePharma inhaler meets clinical study goals pharmiweb.co.uk

TechMARK movers: Elan up, SkyePharma lower

LONDON (ShareCast) - Shares in Elan were higher again today after the Irish biotech said Tuesday that preliminary findings from a Phase 2 study of bapineuzumab in patients with mild to moderate Alzheimer's disease justified the...

analysis/comments

1 2 next

               

Send to a friend | Bookmark with | Subscribe to this